FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy

SPOTLIGHT: Clarus closes $500M fund

Tools

The newly formed Clarus Ventures has closed its first life sciences fund with $500 million. The venture group plans to focus primarily on US biopharmaceutical and specialty pharma companies. Release


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceBiotech Email Newsletter:

More stories about pharmaceutical companies   Clarus Ventures   Biotech Venture Capital